Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Changchun
Clinical trial register · China

Clinical Trials in Changchun, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19224 matching records held by the registry are in this view. Synced 11 Nov 2026, 03:17 UTC
19224
Studies in scope
all four open statuses
11811
Recruiting now
open to new participants
2030
Lead sponsors
across recruiting studies
Top sites
Beijing 5586 Shanghai 3885 Guangzhou 3356 Hangzhou 1825 Wuhan 1342
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca105 The First Hospital of Jilin University49 Hoffmann-La Roche31 Janssen Research & Development, LLC30 Eli Lilly and Company25 Novartis Pharmaceuticals21 Daiichi Sankyo18 Boehringer Ingelheim15 Sanofi12 Pfizer11 Jilin University8 Yi Yang8 GlaxoSmithKline7 Gilead Sciences7 AbbVie6 Merck Sharp & Dohme LLC5 Amgen5 BioNTech SE5 UCB Biopharma SRL5 Biotheus Inc.5 Ou Bai, MD/PHD4 Second Hospital of Jilin University4 Changchun GeneScience Pharmaceutical Co., Ltd.4 FengYan Jin4 Genmab4 Shanghai Jiao Tong University School of Medicine3 Takeda3 Peking Union Medical College Hospital3 MindRank AI Ltd3 Changchun Intellicrown Pharmaceutical Co. LTD3 Hutchmed3 Betta Pharmaceuticals Co., Ltd.3 Dizal Pharmaceuticals3 Northeast Normal University3 Tongji Hospital3 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.3 Acerta Pharma BV3 Abbisko Therapeutics Co, Ltd3 Yehui Tan3 Eisai Inc.3 China-Japan Union Hospital3 Novo Nordisk A/S3 Weill Medical College of Cornell University3 Beijing Tiantan Hospital3 Alexion Pharmaceuticals, Inc.3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.3 Bristol-Myers Squibb3 Shanghai Pharmaceuticals Holding Co., Ltd2 Sun Yat-sen University2 Haisco Pharmaceutical Group Co., Ltd.2 Shanghai Jiaolian Drug Research and Development Co., Ltd2 Beijing InnoCare Pharma Tech Co., Ltd.2 Second Affiliated Hospital, Zhejiang University, School of Medicine2 Nanfang Hospital, Southern Medical University2 EMD Serono Research & Development Institute, Inc.2 Qilu Pharmaceutical Co., Ltd.2 CStone Pharmaceuticals2 Beijing Anzhen Hospital2 Cascade Pharmaceuticals, Inc2 Liu Hongfang2 Astellas Pharma Global Development, Inc.2 Shengjing Hospital2 Genentech, Inc.2 Southeast University, China2 Shanghai Pulmonary Hospital, Shanghai, China2 Shanghai Henlius Biotech2 Nanjing Leads Biolabs Co.,Ltd2 Sichuan Baili Pharmaceutical Co., Ltd.2 RemeGen Co., Ltd.2 Shanghai Junshi Bioscience Co., Ltd.2 Daehwa Pharmaceutical Co., Ltd.1 Ying Gao1 Beijing Children's Hospital1 Advenchen Laboratories Nanjing Ltd.1 MediLink Therapeutics (Suzhou) Co., Ltd.1 CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.1 Epizyme, Inc.1 Pierre Fabre Medicament1 Suzhou BlueHorse Therapeutics Co., Ltd.1 Xuanwu Hospital, Beijing1 ADC Therapeutics S.A.1 Shanghai HEP Pharmaceutical Co., Ltd.1 Jinling Hospital, China1 Jacobio Pharmaceuticals Co., Ltd.1 Karyopharm Therapeutics Inc1 Songling Zhang1 Shanghai Weihe Medical Laboratory Co., Ltd.1 Zai Lab (Shanghai) Co., Ltd.1 Peking University People's Hospital1 Jiangsu Alphamab Biopharmaceuticals Co., Ltd1 Viatris Innovation GmbH1 Aligos Therapeutics1 Suzhou Suncadia Biopharmaceuticals Co., Ltd.1 4D Molecular Therapeutics1 Foresight Therapeutics (Hefei) Co., Ltd.1 MSD R&D (China) Co., Ltd.1 Beeline Medicines Corporation1 Jianmin Pharmaceutical Group Co., LTD.1 Corxel Pharmaceuticals1 Ton-Bridge Medical Tech. Co., Ltd1 Epygenix1 OriCell Therapeutics Co., Ltd.1 First Hospital of China Medical University1 LEO Pharma1 Anthos Therapeutics, Inc.1 Dong Zhang1 Jilin Heart Hospital1 Lifetech Scientific (Shenzhen) Co., Ltd.1 DualityBio Inc.1 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company1 SPH Sine Pharmaceutical Laboratories Co., Ltd.1 Gracell Biotechnologies (Shanghai) Co., Ltd.1 Chunyan Ma1 Elpiscience (Suzhou) Biopharma, Ltd.1 Shanghai Jiatan Pharmatech Co., Ltd1 Chinese SLE Treatment And Research Group1 Chongqing Jinsaixing Medical Technology Co., Ltd1 Shanghai University of Traditional Chinese Medicine1 Bayer1 Nanjing IASO Biotechnology Co., Ltd.1 Excyte Biopharma Ltd1 Stryker Neurovascular1 tongweihua1 Sinocelltech Ltd.1 Dizal (Jiangsu) Pharmaceutical Co., Ltd.1 Xuanzhu Biopharmaceutical Co., Ltd.1 Shanghai Zhimeng Biopharma, Inc.1 City University of Hong Kong1 jiuwei cui1 manxiaxia1 Geneplus-Beijing Co. Ltd.1 Chengdu Suncadia Medicine Co., Ltd.1 Celgene1 InnoCare Pharma Inc.1 Suzhou Siran Biotechnology Co.,Ltd.1 Beijing Hospital1 Parr Biotechnology (Hebei) Co., Ltd.1 European Myeloma Network B.V.1 Pentax Medical1 Xynomic Pharmaceuticals, Inc.1 Astellas (Beijing) Pharmaceutical R&D Co., Ltd.1 Peking University Hospital of Stomatology1 Tang-Du Hospital1 oubai, MD/PhD1 Eye & ENT Hospital of Fudan University1 The Cleveland Clinic1 Hangzhou Endonom Medtech Co., Ltd.1 Shanghai QuietD Biotechnology Co., Ltd.1 Hangzhou Sumgen Biotech Co., Ltd.1 Jiangsu Jingze Biopharmaceutical Co., Ltd.1 Institute of Hematology & Blood Diseases Hospital, China1 Smith & Nephew, Inc.1 Shanghai Simnova Biotechnology Co.,Ltd.1 Jiangsu Simcere Pharmaceutical Co., Ltd.1 Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany1 Alpine Immune Sciences Inc, A Subsidiary of Vertex1 Chinese PLA General Hospital1 Laekna Limited1 Ausper Biopharma Co., Ltd.1 Candid Therapeutics1 Jazz Pharmaceuticals1 Tasly Pharmaceutical Group Co., Ltd1 Di Wu1 Kexiang Liu, MD1 Healthgen Biotechnology Corp.1 Beijing Continent Pharmaceutical Co, Ltd.1 Huahui Health1 Ruijin Hospital1 Ascentage Pharma Group Inc.1 LeonaBio1 Shanghai Best-Link Bioscience, LLC1 OBI Pharma, Inc1 Children's Hospital of Soochow University1 Allist Pharmaceuticals, Inc.1 Newish Biotech (Wuxi) Co., Ltd.1 Klus Pharma Inc.1 Vertex Pharmaceuticals Incorporated1 Alnylam Pharmaceuticals1 Jiangsu Hansoh Pharmaceutical Co., Ltd.1 Sinotau Pharmaceutical Group1 Shenzhen Kexing Pharmaceutical Co., Ltd.1 Ascentawits Pharmaceuticals, Ltd1 AriBio Co., Ltd.1 Chinese Academy of Medical Sciences, Fuwai Hospital1 Tianjin Medical University Cancer Institute and Hospital1 Taiho Oncology, Inc.1 ArriVent BioPharma, Inc.1 Fudan University1 Xiamen Amoytop Biotech Co., Ltd.1 Zhejiang Doer Biologics Co., Ltd.1 Mirum Pharmaceuticals, Inc.1 Innovent Biologics (Suzhou) Co. Ltd.1 Chipscreen Biosciences, Ltd.1 Mundipharma (China) Pharmaceutical Co. Ltd1 Shouchun Wang, MD, PhD1 argenx1 B. Braun Medical International Trading Company Ltd.1 Harbin Medical University1 Zan Wang1 Ipsen1
Site location
Beijing5586 Shanghai3885 Guangzhou3356 Hangzhou1825 Wuhan1342 Chengdu1310 Nanjing1213 Changsha1159 Chongqing1081 Fuzhou1043 Tianjin937 Zhengzhou930 Hefei901 Jinan788 Changchun640 Shenzhen582 Harbin549 Nanchang445 Xi'an442 Nanning439 Suzhou427 Shenyang407 Xiamen392 Shijiazhuang348 Lanzhou272 Bengbu218 Wenzhou189 Kunming187 Guiyang182 Qingdao171 Luoyang156 Ningbo152 Taiyuan148 Foshan144 Dalian135 Xuzhou134 Haikou124 Changzhou124 Dongguan106 Shantou101 Nantong99 Hong Kong98 Wuhu92 Wuxi84 Huizhou83 Baoding83 Anyang83 Baotou82 Zhuhai79 Guangdong76 Xi’an71 Liuzhou70 Cangzhou63 Zhongshan60 Hohhot59 Ganzhou57 Xinxiang57 Taizhou55 Yangzhou55 Jiangmen54 Guilin54 Ürümqi52 Guanzhou51 Yiwu50 Zhanjiang48 Zhejiang47 Yinchuan47 Linyi47 Meizhou46 Fuyang46 Nanyang45 Zunyi45 Zhangzhou44 Quanzhou43 Jinhua43 Hanzhou42 Changde42 Lishui42 Huzhou41 Huai'an39 Langfang38 Jining37 Jiaxing37 Fujian36 Tangshan35 Jilin City34 Xiangyang32 Hunan31 Xining31 Henan31 Binzhou30 Daqing30 Kaifeng29 Shandong28 Yantai28 Changzhi28 Chifeng28 Yichang27 Hengyang27 Chengde27 Xingtai26 Sichuan25 Jingzhou25 Xianyang24 Hubei24 Weifang23 Mianyang23 Shiyan23 Wuzhou22 Hebei22 Haerbin21 Luzhou21 Lianyungang21 Wuwei21 Jiamusi20 Shaoguan19 Nanchong19 Deyang19 Bozhou18 Zhenjiang18 Liaocheng18 Anqing18 Chenzhou18 Putian18 Shanxi18 Yancheng18 Shaoxing17 Handan16 Qingyuan16 Quzhou16 Zibo15 Yulin15 Qinhuangdao15 Shangqiu15 Chizhou15 Guangxi14 Xian14 Maoming14 Pingxiang14 Luoyang Shi14 Haidian13 Guizhou13 Heilongjiang13 Zhenzhou12 Xiangtan12 Dongyang12 Jiaozuo12 Shengyang12 Ha’erbin12 Linfen11 Nanjin11 Kunshan11 Chaoyang11 Huaian11 Yan’an11 Ma’anshan11 Suqian11 Beijin11 Guandong11 Huanggang10 Jiujiang10 Qionghai10 Zhuzhou10 Ankang10 Jieyang10 Longyan10 Heyuan10 Tianjing10 Baise City10 Guigang9 Tongling9 Weinan9 Chuzhou9 Hanzhong9 Neijiang9 Liupanshui8 Heze8 Yueyang8 Zigong8 Jiangxi8 Linhai8 Zhaoqing8 Huaihua8 Shaoyang8 Tai’an8 Qinzhou8 Zhoukou8 Dezhou7 Dongying7 Xuchang7 Hengshui7 Shenzhen Shi7 Ch’ang-ch’un7 Zhangjiakou7 Anhui7 Jinjiang7 Sanming7 Fuzhou Fujian7 Hainan7 Cheng Du Shi7 Lu'an7 Yibin7 Sanya7 Dali7 Huainan7 Baoji7 Xicheng7 Kashgar6 Puyang6 Huangshi6 Suining6 Jinzhou6 Meihekou6 Luohe6 Xuancheng6 Chaoyang District6 Zhoushan6 Kaili6 China6 Yuncheng6 Shanghai Shi6 Naning6 Xuhui6 Dazhou6 Macao5 Enshi5 Anshan5 Yuzhong5 Yixing5 Datong5 Yuhuan5 Dongcheng5 Panjin5 Sanmenxia5 Qianjiang5 Shihezi5 Wanzhou5 Changping5 Jiazhuang5 Mudanjiang5 Haidian District5 Tongliao5 Lanxi5 Bijie5 Zhumadian5 Wenling4 Jiangsu4 Weihai4 Xianning4 Taian4 Benxi4 Qinghai4 Huangshan City4 Ya'an4 Ningde4 Hezhou4 Suzhu4 Jiangyin4 Ji'nan4 Qiqihar4 Chaohu4 Pudong4 Changshu4 Jingdezhen4 Yongzhou4 Multiple Locations4 Jiuquan4 Huangpu4 Gaozhou4 Anning4 Chendu4 Yunnan3 Aksu3 Yanan3 Beijingcun3 Shanwei3 Shunde3 Zhujiang3 Changsha Shi3 Rizhao3 Shapingba3 Bishan3 Dongwan3 Anshun3 Minhang District3 Gansu3 Binhai3 Huaibei3 Chongqicun3 Dengzhou3 Yangpu3 Shang'ai3 Loudi3 Leshan3 Ji’an3 Xingyi3 Guankou3 Fushun3 Fuxin3 Guangdong Province3 Hebi3 Yangjiang3 Neimeng3 Jiyuan3 Zhangjiang3 Lhasa3 Weihui3 Beihai3 Xinjiang3 Yunfu3 Linqing2 Maanshan2 Meishan2 Liangyugang2 Ninghai2 Fuling2 Hechuan2 Yichang Shi2 Guiping2 Karamay2 Taipei2 Ningxia2 Xigazê2 Inner Mongolia2 Pingdingshan2 Yichun2 Herbin2 Gongshu District2 Chongqi2 Tongzhou2 Meicheng2 Tongren2 Baotou Shi2 Xuhui District2 Shatin2 Changzhou Shi2 Hechi2 Jishou2 Huayuan2 Dangyang2 Yixingcun2 Dandong2 Zaozhuang2 Yueqing2 Chibi2 Jingjiang2 Suizhou2 Xiaogan2 Jing’an2 Haozhou2 Dingxi2 Changle2 Macau2 Panlong2 Guli2 Many Locations2 Yisa2 Shanhai2 Lincang2 Xicheng District2 Fengtai2 Jincheng2 Rui’an2 Yiyang2 Xinyang2 Danyang2 Qiandongnan Miao and Dong Autonomous Prefecture2 Qiannan2 Jiaxin2 Xiantao2 Tianshui2 Jinzhong2 Guangyuan2 Nan'ning2 Taiwan2 Qujing2 Taihe Chengguanzhen2 Anxi2 Changlexi2 Hetian1 Yangcheng1 Chengdoucun1 Feicheng1 Jingmen1 Chengdu, Sichuan1 Chancheng District1 Liwan District1 North Street1 Nanshan District1 Luoyan1 Hami1 Liu‘an1 Xianmencun1 Zhenngzhou1 Xichengqu Beijing1 Beijing Sheng1 Gunan1 Jiangjin1 Wulong1 Sanhe1 Ruyang1 Qidong1 Xiangya1 Tongji1 Wujin District1 Guangong Apt/Yuncheng1 Chaozhou1 Jimsar1 Luopu1 Yining1 Tainan1 Taoyuan1 Changchuan1 Guangzhusi1 Zhuozhou1 Fyzhou1 Qingyang1 Lingchuan1 Xing’an1 Daming1 Dingxing1 Zhengding1 Wenquan1 Shangluo1 Ji'an1 Dexing1 Wanzai1 Linxia1 Siping1 Wuhai1 Dongguan Shi1 Pinggu1 Xi'an, China1 Chongli1 Beijing, China1 Beijeing1 Deyang Shi1 Foshan Shi1 Taishing1 Xiameng1 Tongchuan1 Hexi District, Tianjin1 Daping1 Pu'er1 Ezhou1 Chengxiang1 Zheng'zhou1 Heihe1 Lianyuan1 Yongji1 Hongcun1 XiAn1 Zhangjiagang1 Nayong1 Yuzhong District1 Shenyany1 Hengzhou1 Duyun1 Ordos1 Chian1 Guanghzou1 Heifei1 Maoming Shi1 Tiyuan1 Nanzhang Chengguanzhen1 Chongzuo1 Laibin1 Pinghu1 Guangxi Zhuang Autonomous Region1 Fulingqu1 Siming1 Changning1 Lingbao1 Fengcheng1 Beijjing1 Zhangye1 Yizheng1 Junxian1 Pingdu1 Zouping1 Huozhou1 Jiexiu1 Hegang1 Shuangyashan1 Suihua1 Louxing District1 Guang’an1 Dongfang1 Minhang1 Shancheng1 Yangzhou SHI1 Cangzhou Shi1 Chongging1 Linquan County1 Guangdong Province Guangzhou City1 Fenyang1 Jiayuguan1 Liangshan1 Ziyang1 Shenzhencun1 Zhaotong1 Yingtan1 Xiangshan1 Liaoyou1 Taihe1 Zhangping1 Longzhou1 Bingjie1 Gannan1 Hexi District1 Jixi1 Yangchun1 Sanjiaocheng1 Chuangchun1 Daozhen Klau and Hmong Autonomous County in Zun'yi1 Qiandongnan Miao and Dong Autonomous Region1 Jina1 Chang’an1 Cili1 Lanshan1 Leiyang1 Pingjiang1 Yangzhong1 Tianmen1 XI 'an City, Shaanxi Province1 Laizhou1 Qinhuangdao Shi1 Linyi Shi1 Linping1 Qingzhen1 Ningxiang1 Jianli City, Jingzhou City1 Jingxi1 Tengzhou Town1 Xiangyang City, Hubei Province1 Changcun1 Chongoing1 Zunhua1 Mengzhou1 Nanle1 Pizhou1 Changshang1 Yanji1 Gu'ang'zhou1 Ulanhot1 Jihan1 Hubei Sheng1 Wenshan Zhuang and Miao Autonomous Prefecture1 Anhui Sheng1 Zhongshan Town1 Yushu1 Sichuan Chengdu1 Jiangse1 Binzhou Shi1 Changhua1 Wuhang1 Gengma County1 Xian City1 Baiyin1 Xinle1 Yunlin1 Bayan Nur1 Anning, Yunnan - South Region1 Beijing, Beijing1 Cangzhou, Hebei - North Region1 Caoxian County, Shandong Province1 Changzhou, Jiangsu Province1 Chengdu, Sichuan Province1 Chongqing, Chongqing1 Chongqing, Sichuan Province1 Wu’an1 Fuding1 Zhuji1 Kaiping1 Heping1 GuiZhou1 HuBei1 HuNan1 Baoshan1 Tanjing1 Haizhu1 Shijia Zhuang1 Jiancheng1 Fuqing1 Nanping1 Tanjin1 Jiading1 Shushan1 Lanfang1 Chuxiong1 Puer1 Wenshan1 Hengshui Shi1 Dazhu1 Dingzhou1 Shang’ai1 Feixian1 Gulin1 Hanyang1 Wannan1 Beiliu1 Guidong1 Xizang1 Gongyi1 Fu'zhou1 Wuha1 Tacheng1 Longgang1 Jinghong1 Zhengjiang1 Puning1 Hongkou1 Heifi1 Changshan1 Najing1 Gui'lin1 Hshijiazhuang1 Wuhou District1 Changshashi1 Shanhu1 Xiangyun1 Xinzheng1 Hangzou1 Yongcheng1 Jining Shi1
All 625 locations
Target enrolment
to

Trials with a site in Changchun

640 of 19224 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
By invitation
UCB Biopharma SRL
Phase 3
300
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming
2022-02-03
Recruiting
Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN
NCT05260671Head and Neck Neoplasms, Recurrent Disease, Metastatic Cancer
DrugsPenpulimab·Cetuximab
Eye & ENT Hospital of Fudan University
Phase 2
48
Changchun, Shanghai
2022-01-25
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
290
Beijing, Chongqing, Guangzhou, Luoyang, Zhengzhou, Wuhan, Nanchang, Changchun
2022-01-14
Active, closed
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
176
Chongqicun, Fuzhou, Guangzhou, Changsha, Nanchang, Changchun, Jinan, Xi’an
2022-01-04
Active, closed
Lorlatinib Continuation Study
NCT05144997Non-Small-Cell Lung Cancer, NSCLC
DrugLorlatinib
Pfizer
Phase 4
76
Hefei, Beijing, Fuzhou, Guangzhou, Changsha, Nanjing, Changchun, Hangzhou
2021-12-28
Active, closed
Crizotinib Continuation Clinical Study
NCT05160922NSCLC, ALCL, IMT
DrugCrizotinib
Pfizer
Phase 4
27
Beijing, Fuzhou, Guangzhou, Changchun, Wuhou District, Hangzhou, Shanghai
2021-12-27
Active, closed
Eli Lilly and Company
Phase 3
152
Beijing, Fuzhou, Guangzhou, Harbin, Changsha, Changchun, Xi'an, Jinan
2021-12-20
Recruiting
Merck Sharp & Dohme LLC
Phase 1
830
Beijing, Fuzhou, Guangzhou, Wuhan, Changchun, Shanghai, Hangzhou
2021-12-17
Active, closed
Novartis Pharmaceuticals
Phase 3
1,000
Guangzhou, Zhengzhou, Changsha, Baotou, Hohhot, Nanchang, Changchun, Beijing
2021-12-16
Recruiting
UCB Biopharma SRL
Phase 3
350
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming
2021-12-07
Active, closed
Hoffmann-La Roche
Phase 3
49
Guangzhou, Harbin, Wuhan, Jinan, Hangzhou, Beijing, Changchun, Changsha
2021-12-01
Active, closed
Novartis Pharmaceuticals
Phase 3
153
Fuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Xuzhou, Changchun, Chengdu
2021-11-15
Active, closed
AstraZeneca
Phase 3
454
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan
2021-10-28
Active, closed
Hoffmann-La Roche
Phase 3
478
Beijing, Changchun, Guangzhou, Harbin, Nanchang, Nanjing, Shanghai, Tianjin
2021-10-27
Active, closed
AstraZeneca
Phase 3
732
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou
2021-10-18
Active, closed
Janssen Research & Development, LLC
Phase 3
587
Beijing, Changchun, Changshashi, Chaoyang District, Chengdu, Fuzhou, Guangzhou, Hangzhou
2021-10-14
Active, closed
Gilead Sciences
Phase 2
53
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanjing
2021-10-12
Active, closed
Beeline Medicines Corporation
Phase 2
248
Beijing, Shenzhen, Nanjing, Suzhou, Changchun, Dalian, Jinan, Jining
2021-10-11
Active, closed
Hoffmann-La Roche
Phase 3
217
Changchun, Changsha, Chengdu, Guangzhou, Harbin, Jining, Nanning, Shanghai
2021-09-30
Recruiting
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
NCT04930432Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer
DrugMCLA-129
Betta Pharmaceuticals Co., Ltd.
Phase 1/2
400
Baoding, Beijing, Bengbu, Cangzhou, Changchun, Changsha, Chengdu, Chifeng
2021-09-24
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2
333
Fuzhou, Wuhan, Changchun, Hangzhou, Beijing
2021-09-22
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Beijing, Guangzhou, Luoyang, Zhengzhou, Changsha, Changchun, Yinchuan, Taiyuan
2021-09-20
Active, closed
Nanfang Hospital, Southern Medical University
Observational
1,300
Chongqing, Guangzhou, Hebei, Changsha, Nanjing, Xuzhou, Nanchang, Changchun
2021-09-15
Recruiting
FengYan Jin
Observational
131
Changchun
2021-09-08
Recruiting
R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden
NCT05040555Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3B
oubai, MD/PhD
Not applicable
64
Changchun
2021-08-30
Active, closed
Hoffmann-La Roche
Phase 3
4,170
Zhengzhou, Changsha, Nanchang, Changchun, Shanghai, Chengdu, Hangzhou, Beijing
2021-08-27
By invitation
Viatris Innovation GmbH
Phase 3
25,000
Baotou, Beijing, Cangzhou, Changchun, Changsha, Chaoyang District, Chengdu, Chongqing
2021-08-14
Not yet open
The First Hospital of Jilin University
Observational
1,250
Changchun
2021-08-01
Active, closed
GlaxoSmithKline
Phase 3
72
Beijing, Changchun, Guangzhou, Hangzhou, Jinan, Nanjing, Shenyang, Suzhou
2021-07-28
By invitation
UCB Biopharma SRL
Phase 3
760
Beijing, Changchun, Guangzhou, Guilin, Shanghai, Shantou, Suzhou, Tianjin
2021-07-27
Active, closed
Dizal Pharmaceuticals
Phase 2
104
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Haikou, Hangzhou
2021-07-19
Recruiting
Shengjing Hospital
Phase 4
110
Harbin, Changchun, Dalian, Panjin, Shenyang
2021-07-19
Recruiting
Shengjing Hospital
Observational
1,000
Harbin, Changchun, Dalian, Panjin, Shenyang
2021-07-19
Recruiting
Janssen Research & Development, LLC
Phase 3
199
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan
2021-07-15
Recruiting
Boehringer Ingelheim
Phase 1
554
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanning, Shanghai
2021-07-02
Active, closed
Janssen Research & Development, LLC
Phase 3
1,054
Baoding, Baotou, Beijing, Bengbu, Changchun, Changzhou, Chengdu, Chongqing
2021-06-17
Active, closed
D9319C00001- 1L OC Mono Global RCT
NCT04884360Ovarian Cancer
DrugOlaparib
AstraZeneca
Phase 3
366
Baoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang
2021-05-31
Recruiting
Janssen Research & Development, LLC
Phase 1/2
420
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing
2021-05-19
Active, closed
AstraZeneca
Phase 3
893
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou
2021-05-10
Active, closed
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3
192
Changchun
2021-04-30
Active, closed
The GUARDIAN Pilot Trial
NCT04789733General Surgery
The Cleveland Clinic
Not applicable
80
Changchun
2021-04-27
Active, closed
AstraZeneca
Phase 3
1,157
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Guangzhou, Hangzhou
2021-04-26
Recruiting
Healthgen Biotechnology Corp.
Phase 2
220
Changchun
2021-03-22
Active, closed
Karyopharm Therapeutics Inc
Phase 2
112
Beijing, Wuhan, Nantong, Suzhou, Changchun, Hangzhou
2021-03-17
Active, closed
Hoffmann-La Roche
Phase 3
746
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Kunming
2021-03-17
Recruiting
MSD R&D (China) Co., Ltd.
Phase 1
100
Beijing, Xiameng, Guangzhou, Shijiazhuang, Zhengzhou, Nanchang, Changchun, Jinan
2021-03-16
Recruiting
AstraZeneca
Phase 1
304
Changchun, Chengdu, Fuzhou, Shandong, Shanghai, Zhengzhou
2021-03-09
Recruiting
Biotheus Inc.
Phase 1/2
380
Baoji, Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chongqing
2021-03-09
Recruiting
Di Wu
Phase 2
40
Changchun
2021-03-01
Active, closed
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
277
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Harbin, Nanjing, Shanghai
2021-02-02
Active, closed
AstraZeneca
Phase 3
1,371
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian
2021-01-28
Active, closed
Jilin University
Not applicable
350
Changchun, Beijing, Chongqing, Guangzhou, Shanghai, Shenyang
2021-01-27
Active, closed
Janssen Research & Development, LLC
Phase 3
518
Beijing, Changchun, Changsha, Changsha Shi, Chengdu, Chongqing, Guangzhou, Hangzhou
2020-12-07
Active, closed
Daiichi Sankyo
Phase 3
1,600
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2020-12-04
Active, closed
Hoffmann-La Roche
Phase 2
303
Changchun, Guangzhou, Linyi, Nanchang, Shanghai, Tianjin, Wuhan, Xi'an
2020-11-27
Active, closed
Gilead Sciences
Phase 3
331
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan
2020-11-23
Recruiting
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
NCT04606446Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
DrugsPrifetrastat·Atirmociclib·Palbociclib·Letrozole
Pfizer
Phase 2
320
Beijing, Guangzhou, Changchun, Xi'an
2020-11-16
Active, closed
AstraZeneca
Phase 1/2
702
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Harbin, Jining
2020-11-12
Active, closed
Gilead Sciences
Phase 2
80
Beijing, Shenyang, Hangzhou, Changchun, Changsha, Chengdu, Chongqing, Guangzhou
2020-10-23
Active, closed
Janssen Research & Development, LLC
Phase 3
308
Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou
2020-10-13
Active, closed
Hoffmann-La Roche
Phase 3
992
Anyang, Baoding, Beijing, Bengbu, Changchun, Changsha, Fujian, Guangzhou
2020-10-09
Active, closed
Acerta Pharma BV
Phase 3
611
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Luoyang
2020-10-08
Active, closed
GlaxoSmithKline
Phase 3
302
Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Jiangsu, Nanchang, Shenyang
2020-10-01
Active, closed
Janssen Research & Development, LLC
Phase 3
1,074
Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Guangzhou, Hangzhou
2020-09-30
Active, closed
ADC Therapeutics S.A.
Phase 3
440
Beijing, Xiamen, Guangzhou, Zhengzhou, Changchun, Dalian, Shanghai, Chengdu
2020-09-16
Recruiting
ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies
NCT04412616Advanced EGFR Positive Solid Tumor
Changchun Intellicrown Pharmaceutical Co. LTD
Phase 1
60
Changchun
2020-09-01
Active, closed
Hoffmann-La Roche
Phase 1/2
237
Changchun, Chengdu, Shanghai, Tianjing, Xiamen
2020-08-12
Active, closed
AstraZeneca
Phase 3
185
Changchun
2020-08-04
Active, closed
AstraZeneca
Phase 3
866
Baoding, Beijing, Changchun, Changsha, Dalian, Foshan, Fuzhou, Guangzhou
2020-07-24
Active, closed
Novartis Pharmaceuticals
Phase 3
19
Changchun, Shanghai
2020-07-16
Active, closed
GlaxoSmithKline
Phase 3
242
Beijing, Changchun, Chongqing, Guangzhou, Nanchang, Nanjing, Shanghai, Tianjin
2020-07-14
Active, closed
AstraZeneca
Phase 3
1,012
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang
2020-07-13
Active, closed
Epizyme, Inc.
Phase 3
599
Fuzhou, Xiamen, Guiyang, Zhejiang, Shijiazhuang, Zhengzhou, Changsha, Changchun
2020-06-11
Active, closed
AstraZeneca
Phase 3
805
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Guangdong, Guangzhou
2020-05-05
Active, closed
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
NCT03932331Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma, Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia
DrugAcalabrutinib
AstraZeneca
Phase 1/2
105
Beijing, Changchun, Changsha, Changzhou, Chengdu, Fuzhou, Haikou, Hangzhou
2020-04-29
Active, closed
Xynomic Pharmaceuticals, Inc.
Phase 2
87
Beijing, Changchun, Chengdu, Dalian, Fuzhou, Guangzhou, Hainan, Hangzhou
2020-04-22
Active, closed
AstraZeneca
Phase 3
818
Baoding, Beijing, Changchun, Chongqing, Dalian, Foshan, Gongshu District, Guangzhou
2020-04-16
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
886
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2020-03-30
Active, closed
The First Hospital of Jilin University
Phase 2
30
Changchun
2020-03-20
Active, closed
Eli Lilly and Company
Phase 2
77
Beijing, Guangzhou, Changsha, Changchun, Jinan, Shanghai, Tianjin, Hangzhou
2020-03-16
Active, closed
Eli Lilly and Company
Phase 3
261
Beijing, Guangzhou, Harbin, Wuhan, Changsha, Changzhou, Changchun, Shanghai
2020-02-17
Active, closed
Hoffmann-La Roche
Phase 2/3
325
Beijing, Changchun, Chongqing, Fujian, Guangzhou, Hangzhou, Harbin, Shanghai
2020-01-29
Active, closed
AstraZeneca
Phase 3
155
Beijing, Changchun, Changsha, Changzhou, Guangzhou, Guiyang, Hangzhou, Hefei
2020-01-20
Recruiting
Alexion Pharmaceuticals, Inc.
Observational
500
Chengdu, Beijing, Changchun, Guangzhou, Jinan, Nanchang, Qingdao, Shijiazhuang
2019-12-02
Active, closed
Geneplus-Beijing Co. Ltd.
Observational
757
Beijing, Shenzhen, Zhengzhou, Changsha, Nanjing, Changchun, Jinzhou, Chengdu
2019-11-12
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,064
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Ganzhou, Guangzhou
2019-09-26
Active, closed
Astellas (Beijing) Pharmaceutical R&D Co., Ltd.
Phase 3
180
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Nanchang, Shanghai
2019-09-11
Active, closed
Janssen Research & Development, LLC
Phase 1
701
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan
2019-09-04
Active, closed
Janssen Research & Development, LLC
Phase 2/3
118
Beijing, Changchun, Chengdu, Guangzhou, Haikou, Hangzhou, Lanzhou, Nanjing
2019-08-15
Recruiting
Bristol-Myers Squibb
Phase 2
1,500
Hefei, Beijing, Guangzhou, Harbin, Changsha, Nanjing, Changchun, Xi'an
2019-08-09
Active, closed
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT04008797Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms
DrugsE7386·Doxorubicin·Lenvatinib·Paclitaxel
Eisai Inc.
Phase 1/2
301
Beijing, Changchun, Fuzhou, Guangzhou, Jinan, Kunming, Shanghai, Shenzhen
2019-07-11
Active, closed
Dizal Pharmaceuticals
Phase 1/2
315
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou
2019-07-09
Active, closed
Ascentage Pharma Group Inc.
Phase 1
80
Guangzhou, Zhengzhou, Changchun
2019-07-04
Recruiting
Beijing Hospital
Not applicable
115
Beijing, Guangzhou, Harbin, Nanjing, Xuzhou, Changchun, Xi'an, Luzhou
2019-07-02
Active, closed
AstraZeneca
Phase 3
587
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Haikou, Hangzhou
2019-07-02
Active, closed
AstraZeneca
Phase 3
923
Beijing, Changchun, Changsha, Chengdu, Foshan, Guangzhou, Guiyang, Haikou
2019-06-25
Active, closed
Eisai Inc.
Phase 3
1,906
Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Changsha, Baotou, Nanjing, Changchun
2019-03-27
Active, closed
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
NCT03816163Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
DrugsZolbetuximab·Nab-paclitaxel·Gemcitabine
Astellas Pharma Global Development, Inc.
Phase 2
393
Beijing, Changchun, Chongqing, Guangdong, Guangzhou, Harbin, Hubei, Jiangsu
2019-03-15
Active, closed
AstraZeneca
Phase 3
724
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Hangzhou, Hefei, Jinan
2019-03-06
Active, closed
Acerta Pharma BV
Phase 3
984
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang
2019-02-25
Active, closed
AstraZeneca
Phase 3
1,407
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Guangzhou
2019-01-04
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Nanjing, Suzhou, Changchun
2018-12-07
Active, closed
OBI Pharma, Inc
Phase 3
575
Beijing, Guangzhou, Nanning, Harbin, Wuhan, Changsha, Nanjing, Changchun
2018-12-05
Active, closed
AstraZeneca
Phase 3
724
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2018-11-30
Active, closed
AstraZeneca
Phase 3
407
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2018-11-27
Active, closed
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
NCT03589326Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
DrugsPonatinib·Imatinib·Cytarabine·Methotrexate
Takeda
Phase 3
245
Zhengzhou, Suzhou, Changchun, Hangzhou, Tianjin
2018-10-04
Active, closed
AstraZeneca
Phase 3
1,246
Beijing, Changchun, Changsha, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan
2018-09-27
Active, closed
AstraZeneca
Phase 3
730
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou
2018-09-27
Active, closed
Hoffmann-La Roche
Phase 3
257
Beijing, Changchun, Chengdu, Fujian, Guangzhou, Hangzhou, Jinan, Shanghai
2018-08-16
Active, closed
AstraZeneca
Phase 3
216
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Linhai
2018-07-19
Active, closed
Janssen Research & Development, LLC
Phase 3
629
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing
2018-03-23
Active, closed
AbbVie
Phase 3
747
Beijing, Xiamen, Guangzhou, Wuhan, Changsha, Nanjing, Nanchang, Changchun
2018-03-21
Recruiting
Randomization of Single vs Multiple Arterial Grafts
NCT03217006Coronary Artery Disease, Heart Diseases
Weill Medical College of Cornell University
Not applicable
4,300
Beijing, Changchun, Shanghai, Taiwan, Tianjin
2018-01-07
Active, closed
Daehwa Pharmaceutical Co., Ltd.
Phase 2/3
549
Hefei, Beijing, Guangzhou, Haikou, Harbin, Zhengzhou, Nanjing, Changchun
2017-12-18
Active, closed
Sanofi
Phase 3
475
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang
2017-12-07
Active, closed
AstraZeneca
Phase 3
1,324
Beijing, Changchun, Changsha, Chengdu, Dalian, Fuzhou, Guangzhou, Hangzhou
2017-10-11
Active, closed
AstraZeneca
Phase 3
1,186
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei
2017-06-01
Active, closed
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 2
360
Beijing, Wuhan, Changsha, Naning, Nanjing, Wuxi, Nanchang, Changchun
2017-05-12
Active, closed
Pfizer
Phase 3
296
Beijing, Changchun, Shanghai, Hangzhou, Guangzhou
2017-04-27
Active, closed
Acerta Pharma BV
Phase 3
635
Beijing, Changchun, Changsha, Chongqing, Dalian, Gongshu District, Haidian District, Harbin
2017-04-05
Active, closed
AstraZeneca
Phase 3
987
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Hangzhou, Hefei
2017-03-27
Active, closed
AbbVie
Phase 3
443
Fuzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Changchun, Shanghai
2017-02-02
Active, closed
AbbVie
Phase 3
950
Guangzhou, Shiyan, Wuhan, Changsha, Nanchang, Changchun, Shenyang, Shanghai
2017-01-31
Active, closed
AstraZeneca
Phase 3
669
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Haikou
2017-01-02
Recruiting
Shanghai University of Traditional Chinese Medicine
Observational
50,000
Shenzhen, Ganzhou, Jinan, Kunming, Beijing, Changchun, Guangzhou, Lanzhou
2016-11
Active, closed
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
NCT02864992Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
DrugTepotinib
EMD Serono Research & Development Institute, Inc.
Phase 2
337
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei
2016-09-13
Active, closed
Janssen Research & Development, LLC
Phase 1
751
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangong Apt/Yuncheng, Hangzhou, Hefei
2016-05-24
Active, closed
Novartis Pharmaceuticals
Phase 4
233
Guangzhou, Changchun, Beijing
2015-12-11
Active, closed
AstraZeneca
Phase 3
953
Beijing, Changchun, Chongqing, Guangzhou, Hangzhou, Shanghai, Ürümqi, Wuhan
2015-11-03
Active, closed
AstraZeneca
Phase 3
1,126
Beijing, Changchun, Changsha, Chongqing, Hangzhou, Nanjing, Shanghai, Shenyang
2015-11-02
Active, closed
AstraZeneca
Phase 3
682
Beijing, Changchun, Dalian, Guangzhou, Hangzhou, Kunming, Nanjing, Nanning
2015-10-21
Active, closed
Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature
NCT02375620Short Stature Children Born Small for Gestational Age (SGA)
DrugPEG-somatropin
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 2
96
Beijing, Wuhan, Changsha, Wuxi, Nanchang, Changchun, Shanghai, Taiyuan
2015-04-23
Active, closed
Hoffmann-La Roche
Phase 3
154
Beijing, Changchun, Chengdu, Hangzhou, Harbin, Nanjing, Shanghai, Shenyang
2015-02-02
Active, closed
Eli Lilly and Company
Phase 3
453
Beijing, Changchun, Changzhou, Chengdu, Haikou, Hangzhou, Hefei, Nanning
2014-10-03
Active, closed
AstraZeneca
Phase 3
1,837
Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Jinan, Nanjing
2014-04-22
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2013-08-26
Recruiting
Shanghai Jiao Tong University School of Medicine
Phase 1
300
Ganzhou, Changchun, Shanghai
2013-01
Active, closed
Genentech, Inc.
Phase 2
378
Beijing, Changchun, Guangzhou, Hangzhou, Harbin, Nanjing, Shanghai
2008-10-16
Recruiting
Shanghai Jiao Tong University School of Medicine
Phase 1
500
Changchun, Shanghai
2008-01
Rows per page Showing 501–640 of 640
Previous 1 2
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 November 2026. https://priyalifescience.com/clinical-trials-china/city/changchun?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,224 studies in total at the last sync on 11 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 640 of those studies with a site in Changchun.

How many clinical trials are recruiting in Changchun?

334 of the 640 studies on this page are recruiting new participants as of the 11 Nov 2026, 03:17 UTC sync. A further 58 have not yet opened recruitment, 237 are active but closed to new participants, and 11 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.